Calibrating Models in Economic Evaluation A Seven-Step Approach

被引:108
作者
Vanni, Tazio [1 ,2 ]
Karnon, Jonathan [3 ]
Madan, Jason [4 ]
White, Richard G. [2 ]
Edmunds, W. John [2 ]
Foss, Anna M. [2 ]
Legood, Rosa [1 ]
机构
[1] Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Serv Res Unit, London WC1E 7HT, England
[2] Univ London London Sch Hyg & Trop Med, Ctr Math Modelling Infect Dis, London WC1E 7HT, England
[3] Univ Adelaide, Sch Populat Hlth & Clin Practice, Adelaide, SA, Australia
[4] Univ Bristol, Acad Unit Primary Hlth Care, Bristol, Avon, England
关键词
NATURAL-HISTORY MODEL; FEMALE SEX WORKERS; COST-EFFECTIVENESS; MEDICATION ERROR; CERVICAL-CANCER; VACCINATION; UNCERTAINTY; PREVALENCE; INTERVENTION; SENSITIVITY;
D O I
10.2165/11584600-000000000-00000
中图分类号
F [经济];
学科分类号
02 ;
摘要
In economic evaluation, mathematical models have a central role as a way of integrating all the relevant information about a disease and health interventions, in order to estimate costs and consequences over an extended time horizon. Models are based on scientific knowledge of disease (which is likely to change over time), simplifying assumptions and input parameters with different levels of uncertainty; therefore, it is sensible to explore the consistency of model predictions with observational data. Calibration is a useful tool for estimating uncertain parameters, as well as more accurately defining model uncertainty (particularly with respect to the representation of correlations between parameters). Calibration involves the comparison of model outputs (e.g. disease prevalence rates) with empirical data, leading to the identification of model parameter values that achieve a good fit. This article provides guidance on the theoretical underpinnings of different calibration methods. The calibration process is divided into seven steps and different potential methods at each step are discussed, focusing on the particular features of disease models in economic evaluation. The seven steps are (i) Which parameters should be varied in the calibration process? (ii) Which calibration targets should be used? (iii) What measure of goodness of fit should be used? (iv) What parameter search strategy should be used? (v) What determines acceptable goodness-of-fit parameter sets (convergence criteria)? (vi) What determines the termination of the calibration process (stopping rule)? (vii) How should the model calibration results and economic parameters be integrated? The lack of standards in calibrating disease models in economic evaluation can undermine the credibility of calibration methods. In order to avoid the scepticism regarding calibration, we ought to unify the way we approach the problems and report the methods used, and continue to investigate different methods.
引用
收藏
页码:35 / 49
页数:15
相关论文
共 66 条
[21]  
Gelman A, 2004, Bayesian Data Analysis, V2nd, DOI DOI 10.1007/S13398-014-0173-7.2
[22]  
Gill P. E., 1981, Practical optimization
[23]   Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination [J].
Goldhaber-Fiebert J.D. ;
Stout N.K. ;
Ortendahl J. ;
Kuntz K.M. ;
Goldie S.J. ;
Salomon J.A. .
Population Health Metrics, 5 (1)
[24]   The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women [J].
Goldie, SJ ;
Weinstein, MC ;
Kuntz, KM ;
Freedberg, KA .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (02) :97-+
[25]   Cost-effectiveness of HPV 16, 18 vaccination in Brazil [J].
Goldie, Sue J. ;
Kim, Jane J. ;
Kobus, Katie ;
Goldhaber-Fiebert, Jeremy D. ;
Salomon, Joshua ;
O'Shea, Meredith K. H. ;
Xavier Bosch, F. ;
de Sanjose, Silvia ;
Franco, Eduardo L. .
VACCINE, 2007, 25 (33) :6257-6270
[26]   Estimates of human immunodeficiency virus prevalence and proportion diagnosed based on Bayesian multiparameter synthesis of surveillance data [J].
Goubar, A. ;
Ades, A. E. ;
De Angelis, D. ;
McGarrigle, C. A. ;
Mercer, C. H. ;
Tookey, P. A. ;
Fenton, K. ;
Gill, O. N. .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY, 2008, 171 :541-567
[27]   Economic evaluation of human papillomavirus vaccination in the United Kingdom [J].
Jit, Mark ;
Choi, Yoon Hong ;
Edmunds, W. John .
BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 (7665) :331-335
[28]   Estimating Progression Rates for Human Papillomavirus Infection From Epidemiological Data [J].
Jit, Mark ;
Gay, Nigel ;
Soldan, Kate ;
Choi, Yoon Hong ;
Edmunds, William John .
MEDICAL DECISION MAKING, 2010, 30 (01) :84-98
[29]  
Karnon J, 2007, HEALTH TECHNOL ASSES, V11, P1
[30]   Cost-utility analysis of screening high-risk groups for anal cancer [J].
Karnon, Jonathan ;
Jones, Roy ;
Czoski-Murray, Carolyn ;
Srnith, Kevin J. .
JOURNAL OF PUBLIC HEALTH, 2008, 30 (03) :293-304